Cypherpunk Technologies Inc. (CYPH) stock
Close on Nov 11, 2026Market cap $215.53MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $215.53M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.55
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$877.00K
- EPS, diluted
- $0.07
- Book value per share
- $0.64
- Diluted shares
- 217M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $2.13
- Open
- $1.99
- Day's range
- $1.87 – $2.15
- Volume
- 17,760,370
- Average volume (20 days)
- 15,228,337
- Beta (5 years)
- 1.49
- 52-week range
- $0.41 – $4.19
- RSI (14 days)
- 40.1
- Volatility (1 year)
- 410.7%
- Relative volume
- 1.64×
- WACC
- 12.4%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CYPH | S&P 500 | Difference | CYPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.0% | -2.4% | −29.6 pts | ||
| 3 months | +194.1% | -1.2% | +195.3 pts | ||
| Year to date | +72.4% | +12.3% | +60.1 pts | ||
| 1 year | +357.1% | +12.4% | +344.7 pts | ||
| 3 years | +44.9% | +78.8% | −33.9 pts | +13.2% | +21.4% |
| 5 years | -91.6% | +75.2% | −166.8 pts | -39.1% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cypherpunk Technologies filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Results
- Results
- Results
- Results
About Cypherpunk Technologies
Pharmaceutical Preparations
Cypherpunk Technologies Inc. is a privacy technology company focused on advancing privacy-preserving infrastructure for the digital economy and developing novel therapies for cancer patients. The company operates two primary segments: its privacy technology business and its biotechnology subsidiary, Leap Therapeutics, Inc. Within its privacy division, the company identifies, develops, and invests in privacy-enhancing technologies, anchored by a digital asset treasury strategy focused on the Zcash network and its native cryptocurrency, ZEC. Through Leap Therapeutics, it researches and develops biomarker-targeted antibody therapies, primarily sirexatamab for colorectal and other cancers, as well as a preclinical antibody program, FL-501, for cachexia. The company serves oncology patients through its therapeutic pipeline while targeting users and participants within the decentralized digital economy.
Company profile, executives and historyCypherpunk Technologies stock: common questions
What is Cypherpunk Technologies's stock price?
CYPH closed at $2.00 on Nov 11, 2026, down 6.10% on the day. Over the past 52 weeks it traded between $0.41 and $4.19.
What is Cypherpunk Technologies's market cap?
Cypherpunk Technologies was worth $215.53M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
Does Cypherpunk Technologies pay a dividend?
No. Cypherpunk Technologies has not paid a cash dividend over the last twelve months.
When does Cypherpunk Technologies report earnings next?
Cypherpunk Technologies is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CYPH stock performed over the past year?
Including dividends, CYPH returned +357.1% over the past year, against +12.4% for the S&P 500.
How many CYPH shares are sold short?
15M shares were sold short at the latest FINRA report, 34.50% of the float, or 1.2 days of average trading volume.
Who are Cypherpunk Technologies's competitors?
Companies most similar to Cypherpunk Technologies by business, industry and size include CBIO, PRLD, PTCHF, KZIA, PHIO.
See a number that looks wrong?